Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Deferasirox (Primary) ; Azacitidine; Colecalciferol
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms GFM-EXVD-AZA
- 09 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 11 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.